Asia-pacific Multiplex Assay Market Forecast 2021-2028

KEY FINDINGS

The Asia-Pacific multiplex assay market is predicted to record a CAGR of 9.70% over the projected years of 2021 to 2028. Factors like the growing number of hospitals across emerging economies, technological advancements in the field of healthcare, the augmenting research and development sector, the rising healthcare reforms, and the increasing demand for healthcare infrastructure are expected to fuel the regional market's growth.

MARKET INSIGHTS

The Asia-Pacific multiplex assay market growth assessment includes the analysis of Vietnam, China, Thailand, Australia & New Zealand, India, South Korea, Indonesia, Japan, and the rest of the Asia-Pacific. As per the statistics issued by GLOBOCAN 2018, 1,157,294 new cancer cases were projected in India, with breast, lip, oral cavity, cervical, and lung cancer as the most prevalent types. In addition, the International Agency for Research on Cancer predicted that this number is expected to increase to 1.55 million by 2030. The increase in the number of overall cases of cancer in India is primarily attributed to major risk factors such as cigarette smoking and the consumption of tobacco.

According to the estimations of the International Agency for Research on Cancer 2018, approximately 277,000 new cases of cancer were recorded in South Korea. The number is anticipated to rise to nearly 368,500 over the upcoming decade. Moreover, the stable growth of multiple assays in the country is predominantly accredited to the mounting demand for quality healthcare as well as the rising need for point-of-care testing (POCT) and molecular testing. Hence, these factors are set to propel the market growth in the Asia-Pacific over the forecasted period.

COMPETITIVE INSIGHTS

Some of the leading companies operating in the market are: Seegene Inc, F. Hoffmann-La Roche Ltd, Bio-Techne Corporation, etc.

Our report offerings include:

• Explore key findings of the overall market

• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

• Market Segmentation cater to a thorough assessment of key segments with their market estimations

• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

• Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

• 1.1. STUDY OBJECTIVES
• 1.2. SCOPE OF STUDY
• 1.3. METHODOLOGY
• 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

• 2.1. MARKET SIZE & ESTIMATES
• 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

• 3.1. KEY DRIVERS
  • 3.1.1. PREFERENCE OF MULTIPLEX ASSAYS OVER CONVENTIONAL ASSAYS
  • 3.1.2. ADOPTION OF PERSONALIZED MEDICINES
• 3.2. KEY RESTRAINTS
  • 3.2.1. UNAVAILABILITY OF SKILLED LAB TECHNICIANS
  • 3.2.2. COMPLIANCE WITH STRICT ENVIRONMENTAL REGULATION

4. KEY ANALYTICS

• 4.1. IMPACT OF COVID-19 ON MULTIPLEX ASSAY MARKET
• 4.2. KEY MARKET TRENDS
• 4.3. PORTER'S FIVE FORCES ANALYSIS
  • 4.3.1. BUYERS POWER
  • 4.3.2. SUPPLIERS POWER
  • 4.3.3. SUBSTITUTION
  • 4.3.4. NEW ENTRY
  • 4.3.5. INDUSTRY RIVALRY
• 4.4. KEY BUYING CRITERIA
• 4.5. OPPORTUNITY MATRIX
• 4.6. VENDOR LANDSCAPE

5. MARKET BY TYPE

• 5.1. PROTEIN-BASED MULTIPLEX ASSAY
• 5.2. NUCLEIC ACID-BASED MULTIPLEX ASSAY
• 5.3. OTHER MULTIPLEX ASSAYS

6. MARKET BY PRODUCT

• 6.1. REAGENTS AND CONSUMABLES
• 6.2. INSTRUMENTS AND ACCESSORIES
• 6.3. SOFTWARE AND SERVICES

7. MARKET BY TECHNOLOGY

• 7.1. MULTIPLEX PROTEIN MICROARRAY
• 7.2. MULTIPLEX PCR
• 7.3. OTHER TECHNOLOGIES

8. MARKET BY APPLICATION

• 8.1. CLINICAL DIAGNOSTICS
• 8.2. RESEARCH AND DEVELOPMENT
• 8.3. COMPANION DIAGNOSTICS

9. MARKET BY END-USER

• 9.1. HOSPITALS
• 9.2. CLINICAL LABORATORIES
• 9.3. RESEARCH INSTITUTES
• 9.4. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10. GEOGRAPHICAL ANALYSIS

• 10.1. ASIA-PACIFIC
• 10.2. MARKET SIZE & ESTIMATES
• 10.3. KEY GROWTH ENABLERS
• 10.4. KEY CHALLENGES
• 10.5. KEY PLAYERS
• 10.6. COUNTRY ANALYSIS
  • 10.6.1. CHINA
  • 10.6.2. JAPAN
  • 10.6.3. INDIA
  • 10.6.4. AUSTRALIA & NEW ZEALAND
  • 10.6.5. SOUTH KOREA
  • 10.6.6. THAILAND
  • 10.6.7. INDONESIA
  • 10.6.8. VIETNAM
  • 10.6.9. REST OF ASIA-PACIFIC

11. COMPETITIVE LANDSCAPE

• 11.1. KEY STRATEGIC DEVELOPMENTS
  • 11.1.1. MERGERS & ACQUISITIONS
  • 11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
  • 11.1.3. PARTNERSHIPS & AGREEMENTS
  • 11.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS, AND DIVESTITURES
• 11.2. COMPANY PROFILES
  • 11.2.1. ABCAM
  • 11.2.2. AGILENT TECHNOLOGIES INC
  • 11.2.3. BECTON, DICKINSON AND COMPANY (BD)
  • 11.2.4. BIO-RAD LABORATORIES INC
  • 11.2.5. BIO-TECHNE CORPORATION
  • 11.2.6. F. HOFFMANN-LA ROCHE
  • 11.2.7. ILLUMINA INC
  • 11.2.8. LUMINEX CORPORATION
  • 11.2.9. MERCK MILLIPORE
  • 11.2.10. OLINK PROTEOMICS AB
  • 11.2.11. QIAGEN NV
  • 11.2.12. RANDOX LABORATORIES LTD
  • 11.2.13. SEEGENE INC
  • 11.2.14. SIEMENS HEALTHINEERS AG
  • 11.2.15. THERMO FISHER SCIENTIFIC INC

LIST OF TABLES

• TABLE 1: MARKET SNAPSHOT - MULTIPLEX ASSAY
• TABLE 2: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
• TABLE 3: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY TYPE, FORECAST YEARS, 2021-2028, (IN $ MILLION)
• TABLE 4: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
• TABLE 5: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028, (IN $ MILLION)
• TABLE 6: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
• TABLE 7: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2021-2028, (IN $ MILLION)
• TABLE 8: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
• TABLE 9: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY APPLICATION, FORECAST YEARS, 2021-2028, (IN $ MILLION)
• TABLE 10: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
• TABLE 11: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY END-USER, FORECAST YEARS, 2021-2028, (IN $ MILLION)
• TABLE 12: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
• TABLE 13: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
• TABLE 14: LEADING PLAYERS OPERATING IN THE ASIA-PACIFIC MULTIPLEX ASSAY MARKET
• TABLE 15: LIST OF MERGERS & ACQUISITIONS
• TABLE 16: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
• TABLE 17: LIST OF PARTNERSHIPS & AGREEMENTS
• TABLE 18: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, AND DIVESTITURES

LIST OF FIGURES

• FIGURE 1: KEY MARKET TRENDS
• FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 3: OPPORTUNITY MATRIX
• FIGURE 4: VENDOR LANDSCAPE
• FIGURE 5: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY TYPE, IN 2020
• FIGURE 6: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY PROTEIN-BASED MULTIPLEX ASSAY, 2021-2028 (IN $ MILLION)
• FIGURE 7: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY NUCLEIC ACID-BASED MULTIPLEX ASSAY, 2021-2028 (IN $ MILLION)
• FIGURE 8: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY OTHER MULTIPLEX ASSAYS, 2021-2028 (IN $ MILLION)
• FIGURE 9: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY PRODUCT, IN 2020
• FIGURE 10: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY REAGENTS AND CONSUMABLES, 2021-2028 (IN $ MILLION)
• FIGURE 11: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY INSTRUMENTS AND ACCESSORIES, 2021-2028 (IN $ MILLION)
• FIGURE 12: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY SOFTWARE AND SERVICES, 2021-2028 (IN $ MILLION)
• FIGURE 13: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, IN 2020
• FIGURE 14: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY MULTIPLEX PROTEIN MICROARRAY, 2021-2028 (IN $ MILLION)
• FIGURE 15: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY MULTIPLEX PCR, 2021-2028 (IN $ MILLION)
• FIGURE 16: ADVANTAGES OF IMMUNOHISTOCHEMISTRY (IHC)
• FIGURE 17: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY OTHER TECHNOLOGIES, 2021-2028 (IN $ MILLION)
• FIGURE 18: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY APPLICATION, IN 2020
• FIGURE 19: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY CLINICAL DIAGNOSTICS, 2021-2028 (IN $ MILLION)
• FIGURE 20: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY RESEARCH AND DEVELOPMENT, 2021-2028 (IN $ MILLION)
• FIGURE 21: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY COMPANION DIAGNOSTICS, 2021-2028 (IN $ MILLION)
• FIGURE 22: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY END-USER, IN 2020
• FIGURE 23: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY HOSPITALS, 2021-2028 (IN $ MILLION)
• FIGURE 24: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY CLINICAL LABORATORIES, 2021-2028 (IN $ MILLION)
• FIGURE 25: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY RESEARCH INSTITUTES, 2021-2028 (IN $ MILLION)
• FIGURE 26: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2021-2028 (IN $ MILLION)
• FIGURE 27: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
• FIGURE 28: CHINA MULTIPLEX ASSAY MARKET, 2021-2028 (IN $ MILLION)
• FIGURE 29: JAPAN MULTIPLEX ASSAY MARKET, 2021-2028 (IN $ MILLION)
• FIGURE 30: INDIA MULTIPLEX ASSAY MARKET, 2021-2028 (IN $ MILLION)
• FIGURE 31: AUSTRALIA & NEW ZEALAND MULTIPLEX ASSAY MARKET, 2021-2028 (IN $ MILLION)
• FIGURE 32: SOUTH KOREA MULTIPLEX ASSAY MARKET, 2021-2028 (IN $ MILLION)
• FIGURE 33: THAILAND MULTIPLEX ASSAY MARKET, 2021-2028 (IN $ MILLION)
• FIGURE 34: INDONESIA MULTIPLEX ASSAY MARKET, 2021-2028 (IN $ MILLION)
• FIGURE 35: VIETNAM MULTIPLEX ASSAY MARKET, 2021-2028 (IN $ MILLION)
• FIGURE 36: REST OF ASIA-PACIFIC MULTIPLEX ASSAY MARKET, 2021-2028 (IN $ MILLION)